Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Rhinosporidiosis is a chronic inflammatory disease frequently occurring in Asia. Surgery is the mainstay of treatment. About 48% of postoperative patients experience recurrence. To prevent recurrence, dapsone is now recommended. Our study aims to determine the appropriateness of dapsone therapy to prevent recurrence of rhinosporidiosis. Methods A survey of 101 patients in the two tertiary care hospitals, Cumilla, Bangladesh, from 15 july, 2016 to 30 June, 2022. Diagnostic nasal endoscopy (DNE) was performed at every step for provisional diagnosis of rhinosporidiosis. Here, 60 patients were treated with dapsone, and 41 were not. Results Males (81.2%) suffered more than females (18.8%). The age range was 5–14 years (38; 37.63%), followed by 15–24 years (30; 29.70%). Rural (85.1%) and poor (70.3%) were more affected. Children were 50 (49.5%) (Age < 18 years), and adults were 51 (50.5%) (Age ≥ 18 years). 26.7% (27) were recurrent cases; postoperative treatment with dapsone was 60 (59.4%); and 41 (40.6%) were not receiving dapsone. Recurrence without dapsone was 5; 4.95%, and with dapsone, 1; .99%. The odds ratio between the two groups was evaluated using binary logistic regression: age odds ratio = 1.105 (1.009–1.210), P=.032. sex odds ratio = .260, .045 = 1.485, P=.130, number of operations odds ratio= .038, .001-.989, P=.052. treatment with dapsone odds ratio = 164.246, 11.736 = 2298.629, P = < .001, and follow-up time in months odds ratio = 1.081, 1.035–1.130, P < .001. Conclusion A positive trend in cure was observed across age groups, treatment with dapsone, and follow-up time; a negative trend was observed for sex and the number of operations in postoperative dapsone therapy for rhinosporidiosis.
Source: Research Square
Author: A H M DELWAR
Institution: Comilla Medical College
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7203752286